MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody.

ABSTRACT: Cancer immunotherapy has been regarded as a promising strategy for cancer therapy by blocking immune checkpoints and evoking immunity to fight cancer, but its efficacy seems to be heterogeneous among patients. Manipulating the gut microbiota is a potential strategy for enhancing the efficacy of immunotherapy. Here, we report that MS-20, also known as "Symbiota®", a postbiotic that comprises abundant microbial metabolites generated from a soybean-based medium fermented with multiple strains of probiotics and yeast, inhibited colon and lung cancer growth in combination with an anti-programmed cell death 1 (PD1) antibody in xenograft mouse models. Mechanistically, MS-20 remodeled the immunological tumor microenvironment by increasing effector CD8⁺ T cells and downregulating PD1 exp

SUBMITTER: Lee PJ 

PROVIDER: S-EPMC11290773 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature